Organon Presents Data on VTAMA Cream’s Impact on Sleep at AAAAI 2026 Annual Meeting
How can we address the significant sleep disturbances that affect children with atopic dermatitis and their families? Organon a global healthcare company dedicated to delivering impactful medicines and solutions for a healthier every day, will present compelling new data at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, Pennsylvania. The findings from the Phase 3 ADORING 1 and ADORING 2 pivotal trials highlight the early and consistent improvements in sleep quality for pediatric patients and their families using VTAMA cream.
In the ADORING 1 and ADORING 2 trials, VTAMA cream demonstrated significant and clinically meaningful improvements in sleep scores as early as week 1, with sustained benefits through week 8. These findings, measured using the Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessments, underscore the potential of VTAMA cream to alleviate a critical aspect of atopic dermatitis management.
Sleep disturbance is a significant problem for children with atopic dermatitis and their families, and one that I always take time to address in my clinic,” said Dr. Mark Boguniewicz, Professor in the Department of Pediatrics, Division of Allergy and Immunology at National Jewish Health and the University of Colorado School of Medicine, and an author of the analysis being presented at the AAAAI meeting. “When a child with atopic dermatitis struggles through the night, parents and caregivers are often awake as well, sharing in the fatigue and emotional stress associated with ongoing sleep disturbance.”
Key Insights at a Glance
- Sleep Improvements: Mean POEM sleep subdomain scores significantly improved with VTAMA cream versus vehicle for children aged 2-6 and 12-17 by week 1.
- Family Impact: Mean DFI sleep subdomain scores also showed significant improvements with VTAMA cream versus vehicle in patients aged 12-15 by week 1 and in children aged 2-6 and 7-11 by week 2.
- Consistent Benefits: Clinically significant improvements in sleep subdomains were observed across all age groups through week 8.
- Safety Profile: The most frequently reported adverse events in the trials were folliculitis, headache, and nasopharyngitis.
The Impact of Sleep Disturbances on Pediatric Atopic Dermatitis
Sleep disturbances are a pervasive and often overlooked aspect of atopic dermatitis, affecting not only the patients but also their families. The POEM and DFI assessments provide valuable insights into the quality of life for these children and their caregivers. The findings from the ADORING trials highlight the immediate and sustained benefits of VTAMA cream in improving sleep quality, which can have far-reaching implications for overall well-being.
These findings demonstrate early and sustained improvements in sleep-related measures, including for those as young as two years of age,” said Juan Camilo Arjona Ferreira, MD, Head of R&D and Chief Medical Officer at Organon. “Sleep disturbance is an important and measurable aspect of pediatric atopic dermatitis, and these positive results reinforce our commitment to advancing therapies that address meaningful treatment outcomes across chronic skin conditions.”
Addressing the Urgency of Sleep Improvement
Just as a well-tuned orchestra requires each musician to play in harmony, effective atopic dermatitis management requires addressing all aspects of the condition, including sleep. Organon’s commitment to developing VTAMA cream reflects a holistic approach to patient care. By targeting sleep disturbances, the company is addressing a critical need that can significantly improve the quality of life for both patients and their families. The early and consistent improvements observed in the ADORING trials underscore the potential of VTAMA cream to make a meaningful difference in the lives of those affected by atopic dermatitis.
Organon’s Commitment to Pediatric Atopic Dermatitis
Organon is taking a proactive stance in addressing the challenges of pediatric atopic dermatitis. The company’s Phase 3 ADORING program, which includes the pivotal trials ADORING 1 and ADORING 2, has demonstrated the efficacy and safety of VTAMA cream in improving sleep quality. The most common adverse events reported in the trials were folliculitis, headache, and nasopharyngitis, consistent with the prescribing information. “We are encouraged by these findings and look forward to continuing to disseminate data that are clinically relevant for patients, caregivers, and prescribers,” said Dr. Arjona Ferreira. Organon’s focus on delivering impactful medicines and solutions aligns with its mission to improve the health and well-being of individuals and communities worldwide.
Future Outlook
The future of atopic dermatitis treatment is evolving, and Organon is at the forefront of this progress. The company’s ongoing commitment to research and development, as evidenced by the ADORING trials, signals a continued focus on addressing the multifaceted challenges of the condition. The upcoming presentation at the AAAAI 2026 Annual Meeting will provide further insights into the potential of VTAMA cream, setting the stage for broader clinical adoption and improved patient outcomes. The FDA’s approval of VTAMA cream for the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older in December 2024 marks a significant milestone in this journey.
Conclusion
The data presented by Organon at the AAAAI 2026 Annual Meeting highlights the significant impact of VTAMA cream on sleep quality for pediatric atopic dermatitis patients and their families. This advancement not only addresses a critical aspect of the condition but also underscores the company’s commitment to delivering meaningful solutions. For healthcare providers and caregivers, these findings offer a promising new tool in the management of atopic dermatitis. How will this new treatment option influence your approach to patient care? Join the conversation in the comments below.
About Atopic Dermatitis (AD)
AD, commonly referred to as eczema, is one of the most prevalent inflammatory skin diseases, affecting an estimated 26 million people in the U.S. alone and up to 10% of adults worldwide.2,3 AD occurs most frequently in children, affecting up to 20% worldwide, including nearly 10 million children in the U.S.3,4 The disease results in itchy, red, swollen, and cracked skin, often on the folds of the arms, back of the knees, hands, face, and neck.2 Itching is an especially bothersome symptom for those with AD, and tends to worsen at night.3
About Organon
Organon is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately, or differently affect women, while expanding access to essential treatments in over 140 markets.
Source link: https://www.businesswire.com/
